

Disclosure of the total number of voting rights and shares as of November 30, 2022

Paris, France, December 7, 2022 - ACTICOR BIOTECH (ISIN: FR00140050J5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today discloses the total number of voting rights and shares as of November 30, 2022 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority).

- Listing Place: Euronext Growth Paris
- ISIN Code : FR00140050J5
- Web site: acticor-biotech.com

Date	Number of shares making up the share capital	Theoretical number of voting rights ⁽¹⁾	Number of voting rights excluding shares stripped of voting rights ⁽²⁾
November 30, 2022	10.545.776	10.545.776	10.504.737

(1) In accordance with Article 223-111 of the AMF's General Regulation, this number of shares is calculated based on all shares carrying the right to vote, including those stripped of voting rights.

(2) The actual voting rights correspond to the total number of voting rights that can be exercised in a general meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares minus the shares without voting rights.

About ACTICOR BIOTECH

Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), which is aiming to develop an innovative treatment for cardiovascular emergencies, including ischemic stroke.

Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody (mAb) fragment directed against a novel target of major interest, platelet glycoprotein VI (GPVI). Glenzocimab inhibits platelet binding to the thrombus without affecting physiological hemostasis, thereby limiting the bleeding risk, particularly in the brain.

In May 2022, Acticor Biotech presented positive results from its Phase 1b/2a study, ACTIMIS, at the ESOC, confirming the safety profile and showing a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group in patients with stroke. The efficacy of glenzocimab is now being evaluated in an international Phase 2/3 study, ACTISAVE, which will include 1,000 patients. In July 2022, Acticor Biotech was granted "PRIME" status by the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke. This designation will allow the company to strengthen its interactions and obtain early dialogues with regulatory authorities.

Acticor Biotech is supported by a panel of European and international investors (Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Mirae Asset Capital, Anaxago, Primer Capital, Mediolanum farmaceutici and the Armesa foundation). Acticor Biotech is listed on Euronext Growth Paris since November 2021 (ISIN: FR00140050J5 – ALACT).

For more information, visit: www.acticor-biotech.com

Contacts

ACTICOR BIOTECH

Gilles AVENARD, MD
CEO and Founder

gilles.avenard@acticor-biotech.com

T. : +33 (0)6 76 23 38 13

Sophie BINAY, PhD

General Manager and CSO

Sophie.binay@acticor-biotech.com

T. : +33 (0)6 76 23 38 13

NewCap

Mathilde BOHIN / Quentin MASSÉ
Investor Relations

acticor@newcap.eu

T. : +33 (0)1 44 71 94 95

NewCap

Arthur ROUILLÉ
Media Relations

acticor@newcap.eu

T. : +33 (0)1 44 71 00 15